TFE3-associated neurodevelopmental disorder: A distinct recognizable syndrome.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
03 2020
Historique:
received: 13 05 2019
revised: 27 09 2019
accepted: 18 11 2019
pubmed: 14 12 2019
medline: 5 1 2021
entrez: 14 12 2019
Statut: ppublish

Résumé

The transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3) gene encodes a transcription factor that regulates embryonic stem cell (ESC) differentiation. Its phosphorylation by the lysosomal Rag GTPase signaling pathway leads to cytoplasmic sequestration and inactivation promoting ESC differentiation and exit from pluripotency. Somatic translocations of this X-linked gene cause papillary renal cell carcinoma in which nuclear accumulation of the TFE3 oncoprotein is one of the most significant histopathologic characteristics. Early this year, Villegas et al. identified missense mutations in a TFE3 domain required for cytoplasmic inactivation as potentially causal for a mosaic human developmental disorder. They published five patients with de novo TFE3 nonsynonymous missense variants, four females and one male, with severe intellectual disability (5/5), coarse facial features (4/5), and Blaschkoid pigmentary mosaicism (4/5). The only male described has somatic mosaicism. All patients had normal brain Magnetic Resonance Imagings (MRIs). We present two unrelated females with this distinctive phenotype including the above triad along with other features not previously well described. Both were found to have de novo heterozygous variants in TFE3 on whole exome sequencing, one nonsynonymous missense, and one canonical splice site variant, thereby expanding the phenotypic and mutational spectrum for this disorder. Interestingly, due to significant coarsening of the facial features, both patients were initially thought to have a lysosomal storage disorder but enzyme screening and brain MRIs were negative.

Identifiants

pubmed: 31833172
doi: 10.1002/ajmg.a.61437
doi:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
TFE3 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

584-590

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Clark, J., Lu, Y. J., Sidhar, S. K., Parker, C., Gill, S., Smedley, D., … Cooper, C. S. (1997). Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 15(18), 2233-2239. https://doi.org/10.1038/sj.onc.1201394
Colaço, A., & Jäättelä, M. (2017). Ragulator-a multifaceted regulator of lysosomal signaling and trafficking. The Journal of Cell Biology, 216(12), 3895-3898. https://doi.org/10.1083/jcb.201710039
Lim, C. Y., & Zoncu, R. (2016). The lysosome as a command-and-control center for cellular metabolism. The Journal of Cell Biology, 214(6), 653-664. https://doi.org/10.1083/jcb.201607005
McRae, J. F., Clayton, S., Fitzgerald, T. W., Kaplanis, J., Prigmore, E., Rajan, D., … Hurles, M. E. (2017). Prevalence and architecture of de novo mutations in developmental disorders. Nature, 542(7642), 433-438. https://doi.org/10.1038/nature21062
Pastore, N., Vainshtein, A., Klisch, T., Armani, A., Huynh, T., Herz, N. J., … Ballabio, A. (2017). TFE3 regulates whole-body energy metabolism in cooperation with TFEB. EMBO Molecular Medicine, 9(5), 605-621. https://doi.org/10.15252/emmm.201607204
Slade, L., & Pulinilkunnil, T. (2017). The MiTF/TFE family of transcription factors: Master regulators of organelle signaling, metabolism, and stress adaptation. Molecular Cancer Research, 15(12), 1637-1643. https://doi.org/10.1158/1541-7786.MCR-17-0320
Villegas, F., Lehalle, D., Mayer, D., Rittirsch, M., Stadler, M. B., Zinner, M., … Betschinger, J. (2019). Lysosomal signaling licenses embryonic stem cell differentiation via inactivation of Tfe3. Cell Stem Cell, 24(2), 257-270. https://doi.org/10.1016/j.stem.2018.11.021
Yin, X., Wang, B., Gan, W., Zhuang, W., Xiang, Z., Han, X., & Li, D. (2019). TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas. Journal of Experimental & Clinical Cancer Research, 38(1), 119. https://doi.org/10.1186/s13046-019-1101-7

Auteurs

Jullianne Diaz (J)

Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.

Seth Berger (S)

Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.

Eyby Leon (E)

Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH